Literature DB >> 12115565

Expression of MUC1 splice variants in benign and malignant ovarian tumours.

Andreas Obermair1, Bernd C Schmid, Leisl M Packer, Sepp Leodolter, Peter Birner, Bruce G Ward, Alex J Crandon, Michael A McGuckin, Robert Zeillinger.   

Abstract

MUC1 is expressed on the surface of ovarian cancer cells. Nine different splice variants of MUC1 have been described, but no study has reported on the expression of MUC1 isoforms in human ovarian cancer. Our study compares patterns of expression of MUC1 splice variants of malignant and benign ovarian tumours. Ovarian tissue samples were taken from patients with benign ovarian tumours (n = 34) and from patients who had surgery for primary (n = 47) or recurrent (n = 8) ovarian cancer. RT-PCR for MUC1 splice variants A, B, C, D, X, Y, Z, REP and SEC was performed and their expression compared to clinical and histopathologic parameters. Variants A, D, X, Y and Z were more frequently expressed in malignant than in benign tumours. All primary ovarian cancer cases were positive for variant REP but negative for variant SEC. No significant association of the expression of MUC1 splice variants with the response to chemotherapy or patient survival could be demonstrated. Expression of MUC1 splice variants A, D, X, Y, Z and REP is associated with the presence of malignancy, whereas expression of MUC1/SEC is associated with the absence of malignancy. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12115565     DOI: 10.1002/ijc.10456

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  17 in total

Review 1.  MUC1 (CD227): a multi-tasked molecule.

Authors:  Vasso Apostolopoulos; Lily Stojanovska; Sharron E Gargosky
Journal:  Cell Mol Life Sci       Date:  2015-08-21       Impact factor: 9.261

2.  Targeting the intracellular MUC1 C-terminal domain inhibits proliferation and estrogen receptor transcriptional activity in lung adenocarcinoma cells.

Authors:  Carolyn M Klinge; Brandie N Radde; Yoannis Imbert-Fernandez; Yun Teng; Margarita M Ivanova; Sabra M Abner; Alexandra L Martin
Journal:  Mol Cancer Ther       Date:  2011-08-23       Impact factor: 6.261

3.  Toward an integrative analysis of the tumor microenvironment in ovarian epithelial carcinoma.

Authors:  Ryan N Serio
Journal:  Cancer Microenviron       Date:  2011-11-23

4.  Combination of MUC1 and MUC4 expression predicts clinical outcome in patients with oral squamous cell carcinoma.

Authors:  Yoshiaki Kamikawa; Yuji Kanmura; Tomofumi Hamada; Norishige Yamada; Muzafar A Macha; Surinder K Batra; Michiyo Higashi; Suguru Yonezawa; Kazumasa Sugihara
Journal:  Int J Clin Oncol       Date:  2014-06-10       Impact factor: 3.402

5.  Specific MUC1 splice variants are correlated with tumor progression in esophageal cancer.

Authors:  Kolsoum Rezaie Kahkhaie; Omeed Moaven; Mohammad Reza Abbaszadegan; Mehdi Montazer; Mehran Gholamin
Journal:  World J Surg       Date:  2014-08       Impact factor: 3.352

6.  MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression.

Authors:  Yoannis Imbert-Fernandez; Brandie N Radde; Yun Teng; William W Young; Chuan Hu; Carolyn M Klinge
Journal:  Exp Eye Res       Date:  2011-08-16       Impact factor: 3.467

7.  Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer.

Authors:  Dongrong Situ; Jian Wang; Yun Ma; Zhihua Zhu; Yi Hu; Hao Long; Tiehua Rong
Journal:  Med Oncol       Date:  2010-11-30       Impact factor: 3.064

Review 8.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

Review 9.  Mechanisms of antitumor and immune-enhancing activities of MUC1/sec, a secreted form of mucin-1.

Authors:  Dan Ilkovitch; Roberto Carrio; Diana M Lopez
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

10.  Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec.

Authors:  Dan Ilkovitch; Diana M Lopez
Journal:  Blood       Date:  2009-02-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.